Robert E. Landry - Jan 2, 2024 Form 4 Insider Report for REGENERON PHARMACEUTICALS, INC. (REGN)

Role
EVP Finance CFO
Signature
/s/**Robert E. Landry
Stock symbol
REGN
Transactions as of
Jan 2, 2024
Transactions value $
-$338,439
Form type
4
Date filed
1/4/2024, 04:19 PM
Previous filing
Dec 29, 2023
Next filing
Jan 8, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction REGN Common Stock Options Exercise $246K +650 +2.98% $378.98 22.5K Jan 2, 2024 Direct
transaction REGN Common Stock Tax liability -$374K -421 -1.87% $888.34 22K Jan 2, 2024 Direct
transaction REGN Common Stock Options Exercise $417K +1.1K +4.99% $378.98 23.1K Jan 3, 2024 Direct
transaction REGN Common Stock Tax liability -$628K -688 -2.97% $912.30 22.4K Jan 3, 2024 Direct
holding REGN Common Stock 270 Jan 2, 2024 By 401(k) Plan

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -650 -3.66% $0.00 17.1K Jan 2, 2024 Common Stock 650 $378.98 Direct F1
transaction REGN Non-Qualified Stock Option (right to buy) Options Exercise $0 -1.1K -6.44% $0.00 16K Jan 3, 2024 Common Stock 1.1K $378.98 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The stock option award vests in four equal annual installments, commencing one year after the date of grant.